Skip to content

Use of Naltrexone in a Clinical Setting

Effectiveness of Naltrexone in a Community Setting

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00000445
Enrollment
300
Registered
1999-11-03
Start date
Unknown
Completion date
2002-09-30
Last updated
2005-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcoholism

Brief summary

This 12-week trial will compare individuals receiving naltrexone or placebo plus substance abuse counseling therapy versus those receiving only substance abuse counseling therapy in a rural, nonacademic setting. A followup period of 12 months is included. The effect on service utilization and the cost of the addition of naltrexone to treatment services for alcohol dependence also will be assessed. The study will expand existing research concerning the effectiveness of naltrexone in clinical trials versus a clinical setting.

Interventions

Sponsors

National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Lead SponsorNIH

Study design

Allocation
RANDOMIZED
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Meets criteria for alcohol dependence (within the past 3 months). * Meets criteria for another substance use disorder (except narcotic dependence) but must identify alcohol as the primary substance of abuse. * Must be able to provide an informed consent. * Consent to random assignment and be willing to commit to possible medication treatment and research follow-up. * Must be eligible for treatment at the Dorchester Alcohol and Drug Commission.

Exclusion criteria

* Meets criteria for opiate dependence. * Clinically significant medical problems such as collagen-vascular disease, cardiovascular, renal, gastrointestinal or endocrine problem that would impair participation or limit medication ingestion. * Hepatocellular disease. * Women who are pregnant, nursing, or not practicing an effective means of birth control. * Currently being prescribed naltrexone. * Known sensitivity or allergy to naltrexone.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026